Triple threat: Low-Dose radiation plus chemo and immunotherapy takes on tough lung cancer
NCT ID NCT05765825
First seen Apr 30, 2026 · Last updated Jun 19, 2026 · Updated 11 times
Summary
This phase 2 trial is testing a new approach for people with extensive-stage small cell lung cancer who have not had prior treatment. It combines low-dose radiation with standard chemotherapy (cisplatin or carboplatin plus etoposide) and the immunotherapy drug serplulimab. The goal is to see if this combination can delay cancer progression and improve survival. The study enrolled 61 participants across multiple centers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cancer Hospital of Shantou University Medical College
Shantou, Guangdong, 515041, China
-
China West Hospital
Chengdu, Sichuan, 610000, China
-
Chongqing University cancer hospital
Chongqing, Chongqing Municipality, 400030, China
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 200032, China
-
GuiZhou Provincial People's Hospital
Guiyang, China
-
LiaoNing Cancer Hospital & Institute
Shenyang, Liaoning, 110801, China
-
Shandong Provincial Hospital
Jinan, Shandong, 250021, China
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, 430022, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
serplulimab (an immunotherapy drug), cisplatin or carboplatin (chemotherapy), etoposide (chemotherapy), and low-dose radiotherapy
What this could lead to
If this works, it could point toward a more effective first-line treatment for extensive-stage small cell lung cancer, potentially improving how long people live without their cancer getting worse.
What could go wrong
This is a small, early-phase (phase 2) study with no comparison group, so results are uncertain. The combination of treatments may cause significant side effects, and it is not yet known if it will be better than standard care.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.